United States

Nuclera extends Series C to $87M to advance Antibody Engineering Platform
Nuclera, a Cambridge- and Boston-based biotechnology company focused on accelerating drug discovery through rapid access to functional proteins, has secured an additional $12 million in Series C funding.

The best Articles in our Network